Biogen Inc., founded in 1978 and headquartered in Cambridge, Massachusetts, is a leading biotechnology company dedicated to discovering, developing, and delivering innovative therapies for neurological diseases. Its key products include treatments for multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease, positioning Biogen as a significant player in the biotech sector.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| BIIB 2.25% 2030-05-01 USDBiogen Inc. | United States | 2030-05-01 | 2.250 | 4.31 |
| BIIB 3.15% 2050-05-01 USDBiogen Inc. | United States | 2050-05-01 | 3.150 | 5.84 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Biogen began issuing bonds in 2004, with significant issuances including a $1 billion offering in 2017 to fund research and development efforts. The company's bonds typically offer competitive yields compared to industry peers, reflecting its solid credit ratings. In 2021, Biogen notably issued bonds to finance the acquisition of the rights to a new Alzheimer’s treatment, which generated substantial interest in the market.